{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:01:48Z","timestamp":1791856908308,"version":"4.3.4"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:p>We report on successful early eculizumab administration to treat acute antibody-mediated rejection (ABMR) in a highly sensitized kidney transplant recipient. The recipient is a 7-year-old boy who received, 6 months after a desensitization protocol with monthly intravenous immunoglobulin infusion, a second kidney transplant in the presence of low donor-specific antibodies (DSAs). Both pretransplant lymphocytotoxic and flow cytometric crossmatch were negative. Allograft function recovered promptly, with excellent initial function. On postoperative day (POD) 4, the child developed significant proteinuria with an acute rise in serum creatinine. Allograft biopsy showed severe acute ABMR. Intravenous eculizumab (600 mg), preceded by a single session of plasmapheresis, was administered on POD 5 and 12 along with a 4-day thymoglobulin course. After the first dose of eculizumab, a strikingly rapid normalization of allograft function with a decrease in proteinuria occurred. However, because circulating DSA levels remained elevated, the child received 3 doses of intravenous immunoglobulin (POD 15, 16, and 17), with a significant subsequent decrease in DSA levels. At 9 months after transplant, the child continues to maintain excellent allograft function with undetectable circulating DSA levels. This unique case highlights the potential efficacy of using early eculizumab to rapidly reverse severe ABMR in pediatric transplantation, and therefore it suggests a novel therapeutic approach to treat acute ABMR.<\/jats:p>","DOI":"10.1542\/peds.2014-2275","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T01:35:06Z","timestamp":1422322506000},"page":"e551-e555","source":"Crossref","is-referenced-by-count":39,"title":["Eculizumab to Treat Antibody-Mediated Rejection in a 7-Year-Old Kidney Transplant Recipient"],"prefix":"10.1542","volume":"135","author":[{"given":"Hassib","family":"Chehade","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Lausanne University Hospital, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Rotman","sequence":"additional","affiliation":[{"name":"Transplantation Center, Lausanne University Hospital, Lausanne, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Matter","sequence":"additional","affiliation":[{"name":"Transplantation Center, Lausanne University Hospital, Lausanne, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Girardin","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Aubert","sequence":"additional","affiliation":[{"name":"Transplantation Center, Lausanne University Hospital, Lausanne, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pascual","sequence":"additional","affiliation":[{"name":"Transplantation Center, Lausanne University Hospital, Lausanne, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"issue":"2","key":"2021120907030610700_B1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches.","volume":"14","author":"Djamali","year":"2014","journal-title":"Am J Transplant"},{"issue":"11","key":"2021120907030610700_B2","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1111\/j.1600-6143.2005.01086.x","article-title":"Humoral rejection of organ allografts.","volume":"5","author":"Moll","year":"2005","journal-title":"Am J Transplant"},{"issue":"3","key":"2021120907030610700_B3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation.","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2021120907030610700_B4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00007890-199001000-00019","article-title":"The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I\u2013mediated rejection.","volume":"49","author":"Halloran","year":"1990","journal-title":"Transplantation"},{"issue":"6","key":"2021120907030610700_B5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jca.20181","article-title":"A retrospective review of the outcome of plasma exchange and aggressive medical therapy in antibody mediated rejection of renal allografts: a single center experience.","volume":"23","author":"Al-Badr","year":"2008","journal-title":"J Clin Apher"},{"issue":"11","key":"2021120907030610700_B6","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"issue":"11","key":"2021120907030610700_B7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/00007890-199606150-00007","article-title":"Pathologic features of acute renal allograft rejection associated with donor-specific antibody, analysis using the Banff grading schema.","volume":"61","author":"Trpkov","year":"1996","journal-title":"Transplantation"},{"issue":"10","key":"2021120907030610700_B8","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1681\/ASN.V10102208","article-title":"Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries.","volume":"10","author":"Collins","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2021120907030610700_B9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/ki.1993.187","article-title":"Capillary deposition of C4d complement fragment and early renal graft loss.","volume":"43","author":"Feucht","year":"1993","journal-title":"Kidney Int"},{"issue":"2","key":"2021120907030610700_B10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.trre.2005.05.001","article-title":"C4d deposition in allografts: current concepts and interpretation.","volume":"19","author":"Rotman","year":"2005","journal-title":"Transplant Rev"},{"issue":"8","key":"2021120907030610700_B11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.humimm.2009.04.011","article-title":"Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.","volume":"70","author":"Aubert","year":"2009","journal-title":"Hum Immunol"},{"issue":"1","key":"2021120907030610700_B12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jca.21260","article-title":"Apheresis therapy in children: an overview of key technical aspects and a review of experience in pediatric renal disease.","volume":"28","author":"Hunt","year":"2013","journal-title":"J Clin Apher"},{"issue":"8","key":"2021120907030610700_B13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2021120907030610700_B14","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/j.1600-6143.2008.02441.x","article-title":"Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation.","volume":"8","author":"Burns","year":"2008","journal-title":"Am J Transplant"},{"issue":"1","key":"2021120907030610700_B15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"issue":"9","key":"2021120907030610700_B16","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1111\/j.1600-6143.2010.03191.x","article-title":"Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access.","volume":"10","author":"Lonze","year":"2010","journal-title":"Am J Transplant"},{"issue":"8","key":"2021120907030610700_B17","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/j.1432-2277.2011.01290.x","article-title":"Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation.","volume":"24","author":"Biglarnia","year":"2011","journal-title":"Transpl Int"},{"issue":"10","key":"2021120907030610700_B18","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.transproceed.2012.03.053","article-title":"Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant.","volume":"44","author":"Stewart","year":"2012","journal-title":"Transplant Proc"},{"issue":"1","key":"2021120907030610700_B19","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/petr.12187","article-title":"Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody.","volume":"18","author":"Ghirardo","year":"2014","journal-title":"Pediatr Transplant"},{"issue":"9","key":"2021120907030610700_B20","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1111\/j.1600-6143.2012.04124.x","article-title":"Antibody mediated rejection associated with complement factor h-related protein 3\/1 deficiency successfully treated with eculizumab.","volume":"12","author":"Noone","year":"2012","journal-title":"Am J Transplant"},{"issue":"4","key":"2021120907030610700_B21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00467-010-1708-6","article-title":"Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.","volume":"26","author":"Al-Akash","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"2021120907030610700_B22","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-1787","article-title":"Eculizumab as first-line therapy for atypical hemolytic uremic syndrome","volume":"133","author":"Christmann","year":"2014","journal-title":"Pediatrics"},{"issue":"5","key":"2021120907030610700_B23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/13543784.16.5.625","article-title":"New treatments for acute humoral rejection of kidney allografts.","volume":"16","author":"Venetz","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"2021120907030610700_B24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1097\/00007890-199812150-00008","article-title":"Plasma exchange and tacrolimus\u2013mycophenolate rescue for acute humoral rejection in kidney transplantation.","volume":"66","author":"Pascual","year":"1998","journal-title":"Transplantation"},{"issue":"12","key":"2021120907030610700_B25","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.healun.2012.09.016","article-title":"Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab.","volume":"31","author":"Dawson","year":"2012","journal-title":"J Heart Lung Transplant"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/2\/e551\/1058669\/peds_2014-2275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/2\/e551\/1058669\/peds_2014-2275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:24:49Z","timestamp":1639099489000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/135\/2\/e551\/33486\/Eculizumab-to-Treat-Antibody-Mediated-Rejection-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,1]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-2275","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,1]]}}}